Journal article · 2020 · Open access

Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway

Xinjian Xu, Ji Lv, Fang Guo, Jing Li, Yitao Jia, Da Jiang, Na Wang, Chao Zhang, Lingyu Kong, Yabin Liu, Yanni Zhang, Jian Lv and 1 more

Frontiers in Microbiology, 11, 814 · Published 30 April 2020 · DOI 10.3389/fmicb.2020.00814

Open PDFView at the publisherCite this paper

In brief

“Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway” is a 2020 journal article by Xinjian Xu and 12 co-authors, published in Frontiers in Microbiology. OpenAlex counts 191 citations as of 22 November 2026, which puts it in the top 8% of works published in 2020 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Microbiology.

Citations
191
Most cited in
2025 (40)
Field-weighted impact
8.86
References
71
Authors
13

Abstract

Colorectal cancer (CRC) appears to be rather refractory to checkpoint blockers except the patient with deficient in mismatch repair (dMMR). Therefore, new advances in the treatment of most mismatch repair proficiency (pMMR) (also known as microsatellite stability, MSS) type of CRC patients are considered to be an important clinical issue associated with programmed death 1 (PD-1) inhibitors. In the present study, we evaluated the effects of gut microbiome of MSS-type CRC tumor-bearing mice treated with different antibiotics on PD-1 antibody immunotherapy response. Our results confirmed that the gut microbiome played a key role in the treatment of CT26 tumor-bearing mice with PD-1 antibody. After PD-1 antibody treatment, the injection of antibiotics counteracted the efficacy of PD-1 antibody in inhibiting tumor growth when compared with the Control group (mice were treated with sterile drinking water). Bacteroides_sp._CAG:927 and Bacteroidales_S24-7 were enriched in Control group. Bacteroides_sp._CAG:927, Prevotella_sp._CAG: 1031 and Bacteroides were enriched in Coli group [mice were treated with colistin (2 mg/ml)], Prevotella_sp._CAG:485 and Akkermansia_muciniphila were enriched in Vanc group [mice were treated with vancomycin alone (0.25 mg/ml)]. The metabolites were enriched in the glycerophospholipid metabolic pathway consistent with the metagenomic prediction pathway in Vanc group, Prevotella_sp._CAG:485 and Akkermansia may maintain the normal efficacy of PD-1 antibody by affecting the metabolism of glycerophospholipid. Changes in gut microbiome leaded to changes in glycerophospholipid metabolism level, which may affect the expression of immune-related cytokines IFN-γ and IL-2 in the tumor microenvironment, resulting in a different therapeutic effect of PD-1 antibody. Our findings show that changes in the gut microbiome affect the glycerophospholipid metabolic pathway, thereby regulating the therapeutic potential of PD-1 antibody in the immunotherapy of MSS-type CRC tumor-bearing mice.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Xu, X., Lv, J., Guo, F., Li, J., Jia, Y., Jiang, D., Wang, N., Zhang, C., Kong, L., Liu, Y., Zhang, Y., Lv, J., & Li, Z. (2020). Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway. Frontiers in Microbiology, 11, 814. https://doi.org/10.3389/fmicb.2020.00814

MLA 9

Xu, Xinjian, et al. “Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway.” Frontiers in Microbiology, vol. 11, 2020, p. 814. https://doi.org/10.3389/fmicb.2020.00814.

Chicago

Xu, Xinjian, Ji Lv, Fang Guo, Jing Li, Yitao Jia, Da Jiang, Na Wang, et al. 2020. “Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway.” Frontiers in Microbiology 11: 814. https://doi.org/10.3389/fmicb.2020.00814.

Harvard

Xu, X. et al. (2020) ‘Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway’, Frontiers in Microbiology, 11, p. 814. doi:10.3389/fmicb.2020.00814.

IEEE

X. Xu et al., “Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway,” Frontiers in Microbiology, vol. 11, p. 814, 2020, doi: 10.3389/fmicb.2020.00814.

BibTeX

@article{xu2020microbiome,
  title     = {{Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway}},
  author    = {Xu, Xinjian and Lv, Ji and Guo, Fang and Li, Jing and Jia, Yitao and Jiang, Da and Wang, Na and Zhang, Chao and Kong, Lingyu and Liu, Yabin and Zhang, Yanni and Lv, Jian and Li, Zhongxin},
  journal   = {Frontiers in Microbiology},
  year      = {2020},
  volume    = {11},
  pages     = {814},
  doi       = {10.3389/fmicb.2020.00814},
  url       = {https://doi.org/10.3389/fmicb.2020.00814}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201322
202033
20213030
20223232
20233333
20242828
20254040
20262323

Its field-weighted citation impact is 8.86: it has been cited 8.86 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers

  • gut microbiota
  • microsatellite stable colorectal cancer
  • antibiotic-induced dysbiosis
  • vancomycin
  • colistin
  • Akkermansia muciniphila
  • Bacteroides
  • Prevotella

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Xu, X., Lv, J., Guo, F., Li, J., Jia, Y., Jiang, D., Wang, N., Zhang, C., Kong, L., Liu, Y., Zhang, Y., Lv, J., & Li, Z. (2020). Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway. Frontiers in Microbiology, 11, 814. https://doi.org/10.3389/fmicb.2020.00814

How many times has this paper been cited?

191 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Microbiology: sign in and open the PDF from this page.

Who wrote this paper?

Xinjian Xu, Ji Lv, Fang Guo, Jing Li, Yitao Jia, Da Jiang, Na Wang, Chao Zhang, Lingyu Kong, Yabin Liu, Yanni Zhang, Jian Lv and 1 more.

What is the DOI of this paper?

10.3389/fmicb.2020.00814, permanently at https://doi.org/10.3389/fmicb.2020.00814. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.